Clinical Breakthrough in Myositis: Argenx Reports Phase 3 Success and Accelerates Pipeline Acquisition
Reading Time: 3 minutes
Success in Phase 3 Study ALKIVIA: The antibody preparation VYVGART Hytrulo meets all primary and secondary endpoints with statistically significant efficacy in autoimmune myositis. Potential First-in-Class Approval: Data show a sustained increase in muscle strength and reduced damage markers in immune-mediated necrotizing myopathy (IMNM). Strategic Billion-Dollar Acquisition: Concurrently, Argenx acquires the US peptide developer Unnatural Products for up to 1, 15 billion US dollars; JPMorgan reaffirms the price target of...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
